Cite
HARVARD Citation
Harrington, K. et al. (n.d.). 408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors. Journal for immunotherapy of cancer. p. A248. [Online].